|Antifibrotic activity of an inhibitor of histone deacetylases in DOCA‐salt hypertensive rats|
A Iyer, A Fenning, J Lim, GT Le, RC Reid, MA Halili, DP Fairlie, L Brown
British journal of pharmacology 159 (7), 1408-1417, 2010
|Diet‐induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism|
J Lim, A Iyer, L Liu, JY Suen, RJ Lohman, V Seow, MK Yau, L Brown, ...
The FASEB Journal 27 (12), 4757-4767, 2013
|C5aR and C3aR antagonists each inhibit diet‐induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling|
J Lim, A Iyer, JY Suen, V Seow, RC Reid, L Brown, DP Fairlie
The FASEB Journal 27 (2), 822-831, 2013
|Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a|
V Seow, J Lim, A Iyer, JY Suen, JK Ariffin, DM Hohenhaus, MJ Sweet, ...
The Journal of Immunology 191 (8), 4308-4316, 2013
|An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats|
A Iyer, J Lim, H Poudyal, RC Reid, JY Suen, J Webster, JB Prins, ...
Diabetes 61 (9), 2320-2329, 2012
|Pathway‐selective antagonism of proteinase activated receptor 2|
JY Suen, A Cotterell, RJ Lohman, J Lim, A Han, MK Yau, L Liu, ...
British journal of pharmacology 171 (17), 4112-4124, 2014
|Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides|
RC Reid, MK Yau, R Singh, J Lim, DP Fairlie
Journal of the American Chemical Society 136 (34), 11914-11917, 2014
|Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists|
V Seow, J Lim, AJ Cotterell, MK Yau, W Xu, RJ Lohman, WM Kok, ...
Scientific Reports 6, 2016
|Downsizing a human inflammatory protein to a small molecule with equal potency and functionality|
RC Reid, MK Yau, R Singh, JK Hamidon, AN Reed, P Chu, JY Suen, ...
Nature communications 4 (1), 1-9, 2013
|Biased signaling by agonists of protease activated receptor 2|
Y Jiang, MK Yau, WM Kok, J Lim, KC Wu, L Liu, TA Hill, JY Suen, ...
ACS Chemical Biology 12 (5), 1217-1226, 2017
|Potent heterocyclic ligands for human complement C3a receptor|
RC Reid, MK Yau, R Singh, JK Hamidon, J Lim, MJ Stoermer, DP Fairlie
Journal of Medicinal Chemistry 57 (20), 8459-8470, 2014
|Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015)|
MK Yau, J Lim, L Liu, DP Fairlie
Expert opinion on therapeutic patents 26 (4), 471-483, 2016
|Three homology models of PAR2 derived from different templates: application to antagonist discovery|
SR Perry, W Xu, A Wirija, J Lim, MK Yau, MJ Stoermer, AJ Lucke, ...
Journal of Chemical Information and Modeling 55 (6), 1181-1191, 2015
|A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human Cancer cells|
Y Jiang, MK Yau, J Lim, KC Wu, W Xu, JY Suen, DP Fairlie
Journal of Pharmacology and Experimental Therapeutics 364 (2), 246-257, 2018
|Potent small agonists of protease activated receptor 2|
MK Yau, JY Suen, W Xu, J Lim, L Liu, MN Adams, Y He, JD Hooper, ...
ACS medicinal chemistry letters 7 (1), 105-110, 2016
|Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a|
RJ Lohman, JK Hamidon, RC Reid, JA Rowley, MK Yau, MA Halili, ...
Nature communications 8 (1), 1-15, 2017
|Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins|
A D. de Araujo, J Lim, KC Wu, Y Xiang, AC Good, R Skerlj, DP Fairlie
Journal of medicinal chemistry 61 (7), 2962-2972, 2018
|Electrophilic Helical Peptides That Bond Covalently, Irreversibly, and Selectively in a Protein–Protein Interaction Site|
AD de Araujo, J Lim, AC Good, RT Skerlj, DP Fairlie
ACS medicinal chemistry letters 8 (1), 22-26, 2017
|Structure− Activity Relationships for Substrate-Based Inhibitors of Human Complement Factor B|
G Ruiz-Gómez, J Lim, MA Halili, GT Le, PK Madala, G Abbenante, ...
Journal of medicinal chemistry 52 (19), 6042-6052, 2009
|Repurposing registered drugs as antagonists for protease-activated receptor 2|
W Xu, J Lim, CY Goh, JY Suen, Y Jiang, MK Yau, KC Wu, L Liu, DP Fairlie
Journal of chemical information and modeling 55 (10), 2079-2084, 2015